Sotrovimab, sold under the brand name Xevudy, is a human neutralizing monoclonal antibody with activity against severe acute respiratory syndrome coronavirus 2, known as SARS-CoV-2. It is under development by GlaxoSmithKline and Vir Biotechnology, Inc. Sotrovimab is designed to attach to the spike protein of SARS-CoV-2. Read more
Information Internet project PharmProm.Net dedicated to the pharmaceutical industry in the world. It contains a contact base of organizations, enterprises, companies associated with the pharmaceutical market. The editorial staff of the PharmProm.Net portal offers cooperation in the field of information promotion and advertising in the pharmaceutical market.